Novavax stock closed at $12.82, up 1.26% and outperforming the broader market decline. The vaccine maker has surged 32.01% over the past month. However, upcoming earnings show mixed signals: EPS expected to improve 46.77% YoY to -$0.33, but revenue projected to fall 28.15% to $50.61 million. Full-year estimates show significant declines with -114.73% EPS change and -66.4% revenue decline. The stock holds a Zacks Rank #3 (Hold) rating.

Novavax has recently attracted investor attention with shares returning +18.4% over the past month, outperforming the S&P 500. However, the company faces significant headwinds including a projected loss of $0.38 per share for the current quarter and declining revenues expected to fall 66.4% for the current fiscal year. The stock received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term.

Novavax (NVAX) closed down 10.31% in recent trading. The vaccine maker faces headwinds with projected quarterly EPS of -$0.37 and revenue expected to decline 39.01% year-over-year to $42.96 million. Full-year estimates show -$0.46 EPS and $357.88 million revenue, representing significant declines. The stock holds a Zacks Rank #4 (Sell) rating with no recent changes to consensus estimates.

Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly.

Novavax stock closed at $10.11, up 1.1% and outpacing the S&P 500's 0.17% gain. However, the vaccine maker faces headwinds with projected quarterly revenue down 39.01% year-over-year and full-year revenue expected to decline 68.15%. The stock holds a Zacks Rank #3 (Hold) rating, with EPS estimates falling 7.86% over the past month.

Moderna reported positive Phase III results for its personalized mRNA cancer therapy (intismeran autogene) developed with Merck, showing significant improvements in recurrence-free and distant metastasis-free survival in melanoma patients. The breakthrough validates Moderna's mRNA platform beyond vaccines and opens opportunities across multiple tumor types, while the company simultaneously expands its respiratory vaccine portfolio with RSV, flu, and combination vaccines to reduce COVID-19 dependence.

Novavax (NVAX) closed at $9.42, up 1.29%, outperforming the S&P 500's 0.86% gain. The stock has appreciated 14.25% over the past month. However, the company faces headwinds with projected quarterly EPS of -$0.22 and revenue expected to decline 39.01% year-over-year. Annual projections show -$0.47 EPS and 68.15% revenue decline. Novavax holds a Zacks Rank of #3 (Hold), with consensus EPS projections down 10.12% in the past 30 days.

A hantavirus outbreak on a cruise ship sparked a biotech rally, but the article argues investors should avoid jumping in. The hantavirus is less contagious than COVID-19 and unlikely to become a global pandemic, limiting vaccine market potential. Even if it does spread widely, predicting which companies will succeed is nearly impossible, as demonstrated by COVID-19 vaccine developers. Better opportunities exist in established vaccine makers with strong pipelines or broad market index funds.

Novavax stock surged 13.16% on Friday, tracking gains in Moderna following the publication of Phase 3 results for Moderna's mRNA-based seasonal flu vaccine in the New England Journal of Medicine. The article also notes Moderna's early-stage hantavirus vaccine research collaboration with the U.S. Army and Korea University. Novavax reported Q1 2025 sales of $139.51 million, beating estimates, though the company posted a net loss of $9 million compared to prior year income.

Novavax shares surged 28% in 2026 following a licensing deal with Pfizer for its Matrix-M adjuvant technology, worth $30M upfront plus up to $500M in milestones. However, the analyst recommends staying away from the stock due to uncertain core business fundamentals, inconsistent revenue from its coronavirus vaccine franchise, pipeline risks including a clinical hold setback, and significant competition in vaccine development.

ImmunityBio surged 17.39% on January 20, 2026, following FDA end-of-phase discussions that outlined a resubmission path for its ANKTIVA therapy in BCG-unresponsive papillary bladder cancer. The stock has more than doubled in five days, driven by triple-digit revenue growth and expanding indications for its primary therapy, though investors should expect continued volatility.

Representative Haley Stevens announced plans to draft articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr., criticizing his healthcare policies and claiming he has caused 'health care chaos' and rising costs.